Enhanced expression of polo-like kinase 3 (PLK3) in human immunodeficiency virus (HIV)-infected cells
AssigneeThe First Hospital of China Medical University
InventorsGuoxin Liang, Hong Shang
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe First Hospital of China Medical University
InventorsGuoxin Liang, Hong Shang
Estimating the term…
Biomarker of HIV or SIV infected cells and its application are provided. The marker is PLK (polo-like kinase). By inhibiting the activity of a PLK protein or clearing the same, the purpose of releasing viruses without activating a repository is achieved, such that the viruses can be detected in a physiological state and can also be recognized and cleared by an immune system or a drug in vivo. Enhancing the activity of the PLK protein directly inhibits the release of viruses in an HIV and/or SIV-infected cell. The present invention provides a new target for diagnosis and antiviral therapy of HIV and/or SIV infection, provides medication basis and guarantee for the early rapid detection and extremely early treatment of virus infection, and has important clinical value.
An in vitro method of enhancing an expression of a PLK3 protein in an HIV-infected cell comprising the step of transfecting the HIV-infected cell with a PLK3 protein expression vector;
Dependencies are inferred from the claim text.